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Objective: To evaluate the prognostic factors affecting survival in esophageal squamous cell Carcinoma (ESCC)
patients with pathologic T0 (ypT0) underwent preoperative radiotherapy.
Patients and methods: Two hundred and ninety-six patients with ESCC who had received preoperative radiotherapy
from 1980 to 2007 were retrospectively analyzed. One hundred patients were ypT0 after preoperative radiotherapy.
Univariate and multivariate analyses were performed to evaluate the predictive impact of residual lymph node status
on overall survival (OS) and progression-free survival (PFS).
Results: Among the originally analyzed 296 patients, 100 (33.7 %) patients had ypT0, including 78 patients (78 %) with
ypT0N0, and 22 patients (22 %) with ypT0N1. The 5-year OS of the total patients was 42.4 %. Patients with ypT0N0 have
significant improved 5-year OS and PFS than ypT0N1 patients (OS: 50.7 % vs 13.6 %, P = 0.004; PFS: 49.6 % vs 13.6 %,
P = 0.003). In multivariate analysis, residual lymph node status was also an independent prognostic factors for OS
(HR: 0.406, 95 % CI: 0.240–0.686, P = 0.001) and PFS (HR: 0.427, 95 % CI: 0.248–0.734, P = 0.002).
Conclusion: Our results indicate that patients with ypT0N0 after preoperative radiotherapy had significantly better OS
and PFS than patients with ypT0N1 in ESCC. Residual nodal metastasis of ESCC patients with pathological complete
response of the primary tumor after neoadjuvant radiotherapy does influence prognosis.
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Outcomes for patients with cancer of the esophagus or
gastroesophageal junction (GEJ) remain poor with sur-
gery alone. A variety of adjuvant treatments have been
studied in an attempt to improve survival. Recently, a lot
of attention has been focused on the neoadjuvant radio-
therapy/chemoradiotherapy (RT/CRT). Preoperative mul-
timodality therapy could improve the rate of tumor
resection, reduce the lymph nodes metastasis, decrease
the rate of local recurrence, and also improve survival.* Correspondence: xiaozefen@sina.com
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creativecommons.org/publicdomain/zero/1.0/Randomized and non-randomized [1–10] trials have
shown about 30 % of patients who underwent preopera-
tive RT or CRT had experienced pathologic complete
response (pCR) in the resected specimen [1–13].
A previous study showed that when reclassified patient
stage according to the AJCC 7th edition TNM criteria
after neoadjuvant CRT, the 5-year overall survival (OS)
of patients with ypT0N1 was significantly lower than
ypT0N0 patients, and similar to pathologic partial re-
sponse (pPR) stage II patients [14]. In addition, Rizk
et al. [6] reported that residual nodal disease was the
most important prognostic factor for the patients with
adenocarcinoma cancer of the esophagus undergoing
CRT followed by surgery. However one study from
Korea reported that residual nodal metastasis was not aicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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ESCC patients underwent preoperative CRT. So the role
of residual lymph node status in predicting prognosis
still needs to be further studied.
Our aim of this study was to evaluate the predictive
effect of residual nodal metastasis for OS and




A total of 296 patients with ESCC who had undergone
neoadjuvant radiotherapy followed by surgery in our
hospital between January 1980 and November 2007 were
retrospectively analyzed. Before treatment start, all pa-
tients underwent a barium swallow, upper gastrointes-
tinal endoscopy, B-type ultrasonography of the neck and
abdomen, collection of blood parameters (including
hematology), and biochemical investigations (including
liver function tests). The inclusion criteria included 1)
Karnofsky performance score ≥80, 2) tumors ≤12 cm in
length on endoscopy and/or barium swallow, 3) the cap-
ability to take semifluid food. The exclusion criteria were
1) hoarseness of the voice, 2) have active bleeding, 3)
perforation of the esophagus, 4) have remote metastasis,
5) prior malignancy history. The cancers in the lower
esophageal sphincter were all identified near the opening
of the sphincter, and no clear invasion into the stomach
was observed. Finally, 100 (33.7 %) patients with primary
tumor pCR were enrolled into this study. The Academic
Committee of Chinese Academy of Medical Sciences ap-
proved this study.
Radiotherapy
The external beam radiotherapy was performed with an
8-MV linear accelerator for the whole 296 patients.
Anterior-posterior-opposed radiation fields (the whole
mediastinum and the left gastroepiploic lymphatic chain)
were used in 284 patients (95.5 %) for conventional
radiotherapy. Intensity-modulated radiotherapy (IMRT)
and three-dimensional conformal radiotherapy (3D-
CRT) was applied in 12 patients (4.5 %). For the 100 pa-
tients with pCR, 95 patients underwent conventional
radiotherapy and 5 patients received 3D-CRT or IMRT.
Gross tumor volume (GTV) defined by a 0.5 cm mar-
gin in the lateral and anterior-posterior directions of the
CT scan. The clinical target volume (CTV) in this study
was re-created using a 3 cm margin in the proximal and
distal direction (following the course of the esophagus)
beyond the barium esophagram, endoscopic examin-
ation. Finally, the planning treatment volume (PTV) was
defined by including additional 1-cm proximal and distal
margins and 0.5 cm radial margin based on the CTV.
95 % of the PTV received 40–44 Gray (Gy) of theprescribed dose with 2 Gy/fraction/day and 5 days per
week. The median dose of radiotherapy was 40Gy. Two
hundred and seventy (91.5 %) patients received 40Gy
and 25 patients (8.5 %) received 42-50Gy.Surgery
Surgery was carried out after median 4 weeks (2–8
weeks) rest after neoadjuvant RT. Two hundred and
forty patients (81.1 %) had undergone R0 resection and
56 patients (18.9 %) had R2 resection. Two-field lymph
node dissection was routinely performed, and three-field
lymph node dissection was performed for patients with
suspected or biopsy proved metastases in the cervical or
supraclavicular lymph nodes. A total of 3577 lymph
nodes were removed for all 296 patients, the median was
11 for each patient (ranging: 1–53). For the 100 patients
with ypT0, 1119 lymph nodes were removed in total and
the median was 10 for each patient (ranging: 1–46).
After surgery, follow-up included a visit to the esopha-
geal cancer clinic every 3–6 months for the first 2 years
and every 6–12 months thereafter. CT scans and esopha-
gogastroscopy assessments were performed every
12 months for the first 5 years and whenever clinically
indicated. The median duration of follow-up was
25 months (range: 6–250 months).Pathological characteristics
A group of pathologists examined the entire specimen
with primary and dissected lymph nodes. Based on the
presence or absence of viable tumor at the primary site,
the specimens were divided into tumor pCR or residual
disease. The tumors were classified as pCR when no
cancer was found at the primary tumors, such that the
following conditions existed: there were no residual tu-
mors in general, the neoplastic cells had completely dis-
appeared, and/or there was fibrosis in the tumor bed,
reduction in vascularity, chronic inflammatory cell infiltra-
tion and scar formation were observed by microscopy.Statistical analysis
All analyses were performed using SPSS 13.0 (SPSS
Inc.). The categorical variables between groups were
compared using Pearson’s Chi square test. OS was
calculated from the date of surgery to the date of
death or the last contact date. PFS was calculated
from the date of surgery to the date of the first ob-
servation of recurrence, date of death or last follow-
up without recurrence. The survival was assessed
using the Kaplan-Meier curve and log-rank test. Cox
proportional model was used for multivariate analysis.
All statistical tests were two-sided with significance
defined as P <0.05.
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Patients
The clinical characteristics of the study patients are
shown in Table 1. For 100 patients with ypT0, the me-
dian age was 55 years (27–78 years). Seventy-eight pa-
tients (78.0 %) were ypT0N0, and 22 patients (22.0 %)
were ypT0N1 after neoadjuvant RT. No significant dif-
ferences existed in clinical characteristics between the
two groups of patients. Among the 22 patients with
ypT0N1, 3 patients had positive node in paracardial and
8 patients had positive node in left gastric artery (1 haveTable 1 Characteristics of esophageal cancer patients grouped
by pathologic N status in patients with pathologic complete









Male(ref) 77 (77.0) 60 (76.9) 17 (77.3)
Female 23 (23.0) 18 (23.1) 5 (22.3)
Age(year 0.746
<65 89 (89.0) 69 (88.5) 20 (90.9)
≥65 11 (11.0) 9 (11.5) 2 (9.1)
The length(cm) 0.321
<6 41 (41.0) 34 (43.6) 7 (31.8)
≥6 59 (59.0) 44 (56.4) 15 (68.2)
The location 0.323
Upper 34 (26.0) 23 (29.5) 3 (13.6)
Middle 63 (63.0) 47 (60.3) 16 (72.7)
Lower 11 (11.0) 8 (10.3) 3 (13.6)
Clinical T stagea 0.729
T2 34 (34.0) 25 (32.1) 9 (40.9)
T3 52 (52.0) 42 (53.8) 10 (45.5)
T4a 14 (14.0) 11 (14.1) 3 (13.6)
Clinical N stagea 0.461
N0(ref) 70 (70.0) 56 (71.8) 14 (63.6)
N1 30 (30.0) 22 (28.2) 8 (36.4)
Clinical stagea 0.791
Stage II 66 (66.0) 52 (66.7) 14 (63.6)
Stage III 34 (34.0) 26 (33.3) 8 (36.4)
Surgery 0.521
Lvor-Lowis ooproperation 64 (64.0) 48 (61.5) 16 (72.7)
Mckeown 36 (36.0) 30 (38.5) 6 (27.3)
Local recurrences 0.418
yes 17 (17.0) 12 (12.0) 5 (22.7)
no 83 (83.0) 66 (66.0) 17 (77.3)
Data are expressed as n (%) unless otherwise specified
AJCC American Joint Committee on Cancer, LNs lymph nodes, SD
standard deviation
a AJCC 2002 staging systempositive node in both section). A total of 67 positive
nodes were dissected for these 22 ypT0N1 patients. 41,
8 and 18 positive nodes were found to metastasis in
mediastinum, pericardial and left gastric artery respect-
ively. Complications within 90 days post operation
includes pneumonia (11 patients), anastomotic site leak-
age (5 patients), and anastomotic site stricture (6 patients).
Postoperative 30-day mortality rate was 3.4 % (n = 10).
Causality of death includes respiratory failure (6 patients)
and myocardial infarction (4 patients).
5-year OS and PFS
The 5-year OS was 42.4 % for ypT0 patients, 50.7 % for
the ypT0N0 group and 13.6 % for the ypT0N1 group.
The 5-year PFS was 41.2 % for ypT0 patients, 49.1 % for
the ypT0N0 group and 13.6 % for the ypT0N1 group.
Patients with N0 status after neoadjuvant radiotherapy
have significant improved 5-year OS and PFS than N1
patients (P = 0.004 and P = 0.003 respectively, Fig. 1a-b).
Univariate and multivariate analysis on overall survival
and progression-free survival
Univariate analyses showed that female, clinical T2 stage,
clinical TNM stage II, ypN0 status improved OS and
PFS significantly (P = 0.017, 0.050, 0.032, 0.004 for OS,
P = 0.038, 0.006, 0.063, 0.008 for PFS, data not shown).
However, age, tumor location, tumor length, clinical N
stage, and the operation style have no impact on OS or
PFS in this study (P > 0.05). In multivariate analysis, ypN
Status was also an independent prognostic factors for
OS (HR: 0.406, 95 % CI: 0.240–0.686, P = 0.001) and PFS
(HR: 0.427, 95 % CI: 0.248–0.734, P = 0.002) after adjust-
ment for gender, age, clinical T stage and TNM stage
(Table 2).
Discussion
Our results showed that OS and PFS of patients with
ypT0N1 after neoadjuvant RT were significantly worse
than those of patients with ypT0N0, which indicated
that residual nodal metastases after neoadjuvant RT does
influence the prognosis of patients with pCR of the pri-
mary tumor underwent preoperative RT plus surgery.
Several randomized clinical trials showed that pCR after
neoadjuvant therapy plus surgery ranged from 11 to
43 % for esophageal carcinoma [1–13, 15–17]. pCR after
CRT is most commonly used to predict survival for
these patients [6, 18–20]. However, published studies are
still insufficient for the prediction of survival in patients
with primary tumor pCR [6, 19].
Rizk et al. [21] reported that residual nodal disease
after CRT was the most important prognostic factor
for the patients with adenocarcinoma of the esopha-
gus undergoing CRT followed by surgery. In their
study, the primary tumor pCR was 52.7 % (48/91)
Fig. 1 a overall survival (OS) curves of patients with primary tumor pCR. b Progression-free survival (PFS) curves of patients with primary tumor
pCR. Patients with ypT0N1 disease have a significantly lower OS and PFS ((P = 0.004 and P = 0.003 respectively)
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ESCC (n = 91). Similar results were also reported by
other studies. Kim et al. [14] reported primary tumor
pCR was 64.6 % (29/45) and the prevalence of
ypT0N1 was 8.9 % (4/45) in a subgroup analysis of ESCC
(n = 45). However, Cho’s study showed residual lymph
node metastases did not significantly influence prognosis
in primary tumor pCR patients in ERCC [22].
In our study, the primary tumor pCR rate was 33.7 %
(100/296) and the prevalence of ypT0N1 was 7.4 % (22/
296) in ESCC. For ypT0N1 patients, the number of
lymph node metastases of 1–3 and ≥4 were 17/100 and
5/100 respectively. The 5-year OS for patients with N,
1–3 N+ and ≥4 N+ were 49.8 %, 17.6 % and 0 respect-
ively (P = 0.0002). In the current study, found lower OS
in patients with higher number of lymph node metasta-
ses, but its predictive role for prognosis needs to be
further investigated with larger samples.
The previous Korean study showed that when reclassi-
fied according to the AJCC 7th edition TNM criteria,
the 5-year survival of patients with ypT0N1 was similar
to pPR stage II patients [14]. Although the 7th edition
AJCC/UICC [23] modified the TNM staging of esopha-
geal carcinoma considering the number of lymph node
metastases in 2009, there is still no conclusion as to
whether the 7th TNM staging criteria could be used for
lymph node metastases staging in ypT0 patients after
preoperative RT [24]. Thus we recommend that futureTable 2 Multivariate analysis of overall survival and progression-free
Characteristics PFS
HR (95 % CI)
Gender (Female vs Male) 1.936 (1.044–3.590)
Age (≥65 vs <65) 0.381 (0.175–0.831)
Clinical T stage (T3-4 vs T2) 0.928 (0.507–1.697)
Clinical TNM stage (III vs II) 0.697 (0.389–1.249)
ypN stage (N1vs N0) 0.427 (0.248–0.734)
Note: HR: hazard ratio, CI: confidence interval, ypN: post-therapy pathologic lymph
response in tumor but residual lymph node metastasis after neoadjuvant radiotherarevisions may take consideration of patients with patho-
logic ypT0N1 for esophageal cancer.
In this study, the clinical target volume for radiation
therapy included areas at risk for microscopic disease
and lesions suspected on PET or CT scan. However, be-
sides mediastinum (41 positive), the residual nodal me-
tastasis was very common in abdominal lymph nodes
(18 positive), especially in the left gastric arterial lymph
nodes (18 positive). This indicated that a careful and
complete dissection of abdominal lymph nodes is im-
portant after neoadjuvant therapy.
This study still has several limitations. First, this is
a retrospective analysis with limited number of pa-
tients; selection bias may exist in unmeasured base-
line characteristics, such as nutrition status, which
may also be a source of confounding. Second, CT
scan hasn’t been used in our institution before 1993
and endoscopic ultrasound hasn’t been used before
2000, so the clinical TNM depended on other exams
such as barium esophagram, endoscopic examination,
B-type abdominal ultrasound, and so on. Third, in
this study only 4.5 % of patients underwent 3D-CRT
or IMRT.
In conclusion, our study indicated that the status of
the residual lymph nodes was significant factor for OS
and PFS in ESCC patients with primary tumor pCR after
preoperative radiotherapy. It is important to achieve a
complete surgical resection of the primary tumor sitesurvival in relation to clinical-pathologic characteristics
OS
P value HR (95 % CI) P value
0.036 2.039 (1.178–3.531) 0.011
0.015 0.481 (0.236–0.980) 0.044
0.808 1.010 (0.575–1.776) 0.972
0.226 0.692 (0.404–1.185) 0.180
0.002 0.406 (0.240–0.686) 0.001
node status; pCR: pathologic complete response; ypT0N1: pathologic complete
py and surgery
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